BOCOM INTL: Concore Jierui Pharmaceutical (09966) target price raised to HK$13, upgraded to "buy" rating.

BOCOM INTL has released a research report stating that it is optimistic about the huge global market potential of Kangning Jeri Pharmaceutical's (09966) ADC product matrix. The firm has raised its revenue forecast for 2025-2027 by 3-8%, raised the target price to 13 Hong Kong dollars, and upgraded its rating to "buy". The firm believes that with KN026 and JSKN003, the company is expected to achieve full-line and multi-subtype coverage in breast cancer, and expand the use of other HER2-expressing solid tumors, securing a place in the HER2 track with differentiated layouts.